Eastgate Biotech Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ETBI research report →
About the company
EastGate Biotech Corp. is a pharmaceutical company specializing in the production and distribution of nutraceuticals. These products are rooted in natural therapies and designed for natural absorption within the body.
- CEO
- Rosella C. Perri
- IPO
- 2014
- Employees
- 2
- HQ
- Toronto, NV, US
Price Chart
- Market Cap
- $6.17M
- P/E
- -1.58
- P/S
- 61.89
- P/B
- -0.59
- EV/EBITDA
- -3.44
- Div Yield
- 0.00%
- Gross Margin
- -110.37%
- Op Margin
- -3282.39%
- Net Margin
- -3553.67%
- ROE
- 40.71%
- ROIC
- 63.23%
- Revenue
- $99.73K · -26.73%
- Net Income
- $-3,544,249 · -136.63%
- EPS
- $-0.00 · -58.33%
- Op Income
- $-3,273,690
- FCF YoY
- 123.31%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 3.42
- Avg Volume
- 104
Get TickerSpark's AI analysis on ETBI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 15, 15 | PERRI ROSE C | other | 0 |
| Jan 15, 15 | PERRI ROSE C | other | 0 |
| Jan 5, 15 | PERRI ROSE C | other | 1,036,475 |
| Nov 9, 14 | PERRI ROSE C | other | 320,400 |
| Jan 5, 15 | GLUSKIN ANNA E | buy | 1,243,750 |
| Jan 5, 15 | GLUSKIN ANNA E | buy | 1,243,750 |
Our ETBI coverage
Recent articles, reports, and earnings notes.
No research on ETBI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ETBI report →Similar companies
Peers in the same neighborhood.